Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: A Cancer and Leukemia Group B 59909 correlative science study

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2081-2090

  Hsi, Eric D ^a   Jung, Sin Ho ^b   Lai, Raymond ^c   Johnson, Jeffrey L ^b   Cook, James R ^a   Jones, Dan ^d   Devos, Sven ^e   Cheson, Bruce ^f   Damon, Lloyd E ^g   Said, Jonathan ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CROSS CANCER INSTITUTE   (Canada)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Ki67; Mantle cell lymphoma; PIM1; Prognosis; Transplant

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; METHOTREXATE; PREDNISONE; PROTEIN KINASE PIM 1; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-PIM-1; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 57049101684     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802419640     Document Type: Article

References (64)

1. Bosch, F., Lopez-Guillermo, A., Campo, E., Ribera, J. M., Conde, E. Piris, M. A. et al. (1998) Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer, 82, pp. 567-575.
2. Campo, E., Raffeld, M. and Jaffe, E. S. (1999) Mantle-cell lymphoma. Semin Hematol, 36, pp. 115-127.
3. Evans, L. S. and Hancock, B. W. (2003) Non-Hodgkin lymphoma. Lancet, 362, pp. 139-146.
4. Fisher, R. I., Dahlberg, S., Nathwani, B. N., Banks, P. M., Miller, T. P. and Grogan, T. M. (1995) A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood, 85, pp. 1075-1082.
5. Ritchie, D. S., Seymour, J. F., Grigg, A. P., Roberts, A. W., Hoyt, R. Thompson, S. et al. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol, 86, pp. 101-105.
6. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. Pro, B. et al. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
7. Thieblemont, C., Antal, D., Lacotte-Thierry, L., Delwail, V., Espinouse, D. Michallet, A. S. et al. (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 104, pp. 1434-1441.
8. Vigouroux, S., Gaillard, F., Moreau, P., Harousseau, J. L. and Milpied, N. (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica, 90, pp. 1580-1582.
9. Zelenetz, A. D. (2006) Mantle cell lymphoma: An update on management. Ann Oncol, 17, pp. iv12-iv14.
10. Fu, K., Weisenburger, D. D., Greiner, T. C., Dave, S., Wright, G. Rosenwald, A. et al. (2005) Cyclin D1-negative mantle cell lymphoma: A clinicopathological study based on gene expression profiling. Blood, 106, pp. 4315-4321.
11. Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M. Campo, E. et al. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, pp. 185-197.
12. Katzenberger, T., Petzoldt, C., Holler, S., Mader, U., Kalla, J. Adam, P. et al. (2006) The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood, 107, p. 3407.
13. Tiemann, M., Schrader, C., Klapper, W., Dreyling, M. H., Campo, E. Norton, A. et al. (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol, 131, pp. 29-38.
14. Argatoff, L. H., Connors, J. M., Klasa, R. J., Horsman, D. E. and Gascoyne, R. D. (1997) Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood, 89, pp. 2067-2078.
15. de Vos, S., Krug, U., Hofmann, W. K., Pinkus, G. S., Swerdlow, S. H. Wachsman, W. et al. (2003) Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol, 12, pp. 35-43.
16. Zhu, Y., Hollmen, J., Raty, R., Aalto, Y., Nagy, B. Elonen, E. et al. (2002) Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol, 119, pp. 905-915.
17. Bachmann, M., Hennemann, H., Xing, P. X., Hoffmann, I. and Moroy, T. (2004) The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): A novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem, 279, pp. 48319-48328.
18. Bachmann, M. and Moroy, T. (2005) The serine/threonine kinase Pim-1. Int J Biochem Cell Biol, 37, pp. 726-730.
19. Hu, Y. L., Passegue, E., Fong, S., Largman, C. and Lawrence, H. J. (2007) Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood, 109, pp. 4732-4738.
20. Mikkers, H., Nawijn, M., Allen, J., Brouwers, C., Verhoeven, E. Jonkers, J. et al. (2004) Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol, 24, pp. 6104-6115.
21. Zippo, A., De Robertis, A., Serafini, R. and Oliviero, S. (2007) PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol, 9, pp. 932-944.
22. Feldman, J. D., Vician, L., Crispino, M., Tocco, G., Marcheselli, V. L. Bazan, N. G. et al. (1998) KID-1, a protein kinase induced by depolarization in brain. J Biol Chem, 273, pp. 16535-16543.
23. van der Lugt, N. M., Domen, J., Verhoeven, E., Linders, K., van der Gulden, H. Allen, J. et al. (1995) Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J, 14, pp. 2536-2544.
24. Wang, Z., Bhattacharya, N., Weaver, M., Petersen, K., Meyer, M. Gapter, L. et al. (2001) Pim-1: A serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci, 2, pp. 167-179.
25. Chen, X. P., Losman, J. A., Cowan, S., Donahue, E., Fay, S. Vuong, B. Q. et al. (2002) Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA, 99, pp. 2175-2180.
26. Kim, K. T., Levis, M. and Small, D. (2006) Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol, 134, pp. 500-509.
27. Leverson, J. D., Koskinen, P. J., Orrico, F. C., Rainio, E. M., Jalkanen, K. J. Dash, A. B. et al. (1998) Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell, 2, pp. 417-425.
28. Lilly, M., Sandholm, J., Cooper, J. J., Koskinen, P. J. and Kraft, A. (1999) The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene, 18, pp. 4022-4031.
29. Peltola, K. J., Paukku, K., Aho, T. L., Ruuska, M., Silvennoinen, O. and Koskinen, P. J. (2004) Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood, 103, pp. 3744-3750.
30. Rainio, E. M., Sandholm, J. and Koskinen, P. J. (2002) Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol, 168, pp. 1524-1527.
31. Amson, R., Sigaux, F., Przedborski, S., Flandrin, G., Givol, D. and Telerman, A. (1989) The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA, 86, pp. 8857-8861.
32. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S. Kurachi, K. et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature, 412, pp. 822-826.
33. Domen, J., van der Lugt, N. M., Laird, P. W., Saris, C. J. and Berns, A. (1993) Analysis of Pim-1 function in mutant mice. Leukemia, 7, pp. S108-S112.
34. van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C. Radaszkiewicz, T. et al. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell, 56, pp. 673-682.
35. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J. Matusik, R. et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell, 4, pp. 223-238.
36. Damon, L. E., Johnson, J., Niedzwiecki, D., Cheson, B. D., Hurd, D. D. Bartlett, N. L. et al. (2006) Immuno-chemotherapy and autologous stem cell transplant for untreated patients with mantle cell lymphoma: CALGB 59909. Blood, 108, p. 774a.
37. Jung, S. H., Owzar, K. and George, S. L. (2005) A multiple testing procedure to associate gene expression levels with survival. Stat Med, 24, pp. 3077-3088.
38. Nodit, L., Bahler, D. W., Jacobs, S. A., Locker, J. and Swerdlow, S. H. (2003) Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol, 34, pp. 1030-1034.
39. Vandenberghe, E., Wolf-Peeters, C., Vaughan Hudson, G, Vaughan Hudson, B, Pittaluga, S. Anderson, L. et al. (1997) The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol, 99, pp. 842-847.
40. Lardelli, P., Bookman, M. A., Sundeen, J., Longo, D. L. and Jaffe, E. S. (1990) Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol, 14, pp. 752-763.
41. Hui, D., Reiman, T., Hanson, J., Linford, R., Wong, W. Belch, A. et al. (2005) Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol, 18, pp. 1223-1231.
42. Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M. Corato, A. et al. (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95, pp. 619-626.
43. Greiner, T. C., Moynihan, M. J., Chan, W. C., Lytle, D. M., Pedersen, A. Anderson, J. R. et al. (1996) p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood, 87, pp. 4302-4310.
44. Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F. Peinado, M. A. et al. (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood, 87, pp. 3351-3359.
45. Kienle, D., Katzenberger, T., Ott, G., Saupe, D., Benner, A. Kohlhammer, H. et al. (2007) Quantitative gene expression deregulation in mantle-cell lymphoma: Correlation with clinical and biologic factors. J Clin Oncol, 25, pp. 2770-2777.
46. Salaverria, I., Zettl, A., Bea, S., Moreno, V., Valls, J. Hartmann, E. et al. (2007) Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol, 25, pp. 1216-1222.
47. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., Van Hoof, A. Kluin-Nelemans, H. C. et al. (2007) A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood, 111, pp. 558-565.
48. Raty, R., Franssila, K., Joensuu, H., Teerenhovi, L. and Elonen, E. (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol, 69, pp. 11-20.
49. Schrader, C., Meusers, P., Brittinger, G., Teymoortash, A., Siebmann, J. U. Janssen, D. et al. (2004) Topoisomerase IIalpha expression in mantle cell lymphoma: A marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia, 18, pp. 1200-1206.
50. Determann, O., Hoster, E., Ott, G., Wolfram Bernd, H, Loddenkemper, C. Leo Hansmann, M et al. (2008) Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 111, pp. 2385-2387.
51. Hilbe, W., Gachter, A., Duba, H. C., Dirnhofer, S., Eisterer, W. Schmid, T. et al. (2003) Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120. Oncol Rep, 10, pp. 15-20.
52. van Sandick, J. W., Baak, J. P., van Lanschot, J. J., Polkowski, W., ten Kate, F J Obertop, H. et al. (2000) Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol, 190, pp. 177-183.
53. de Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W. Lee, A. et al. (2007) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol, 25, pp. 805-812.
54. Holder, S., Zemskova, M., Zhang, C., Tabrizizad, M., Bremer, R. Neidigh, J. W. et al. (2007) Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther, 6, pp. 163-172.
55. Wang, Z., Bhattacharya, N., Mixter, P. F., Wei, W., Sedivy, J. and Magnuson, N. S. (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta, 1593, pp. 45-55.
56. Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T. and Miura, M. (1998) Resistance to Fas-mediated apoptosis: Activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene, 17, pp. 931-939.
57. Aho, T. L., Sandholm, J., Peltola, K. J., Mankonen, H. P., Lilly, M. and Koskinen, P. J. (2004) Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett, 571, pp. 43-49.
58. Shirogane, T., Fukada, T., Muller, J. M., Shima, D. T., Hibi, M. and Hirano, T. (1999) Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity, 11, pp. 709-719.
59. Shay, K. P., Wang, Z., Xing, P. X., McKenzie, I. F. and Magnuson, N. S. (2005) Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res, 3, pp. 170-181.
60. Mochizuki, T., Kitanaka, C., Noguchi, K., Muramatsu, T., Asai, A. and Kuchino, Y. (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem, 274, pp. 18659-18666.
61. Fox, C. J., Hammerman, P. S. and Thompson, C. B. (2005) The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med, 201, pp. 259-266.
62. Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S. Kuppers, R. et al. (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature, 412, pp. 341-346.
63. Goy, A. (2007) Mantle cell lymphoma: Evolving novel options. Curr Oncol Rep, 9, pp. 391-398.
64. Khouri, I. F., Romaguera, J., Kantarjian, H., Palmer, J. L., Pugh, W. C. Korbling, M. et al. (1998) Hyper-CVAD and high-dose methotrexate/ cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol, 16, pp. 3803-3809.